Results 321 to 330 of about 170,525 (342)

Baseline characteristics in the SYNCHRONIZE™‐2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP‐1 receptor dual agonist, for obesity in people with type 2 diabetes

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Survodutide is an investigational glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist that has shown promise for treating obesity and its complications in Phase 2 trials. Two double‐blind, randomized, global Phase 3 trials are designed to assess the efficacy and safety of survodutide for treatment of obesity—SYNCHRONIZE™‐1 in ...
Sean Wharton, Carel W. le Roux, Biykem Bozkurt, Elke Platz, Gabriele Bleckert, Samina Ajaz Hussain, Martina Brueckmann, Elena Startseva, Isabel M. Kloer, Lee M. Kaplan   +9 more
wiley   +1 more source

Metabolic dysfunction‐associated steatotic liver disease, insulin resistance and hepatocellular carcinoma: A deadly triad

European Journal of Clinical Investigation, EarlyView.
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a major global cause of liver disease, driven by obesity and insulin resistance (IR). IR promotes hepatic lipid accumulation, inflammation and mitochondrial dysfunction, accelerating MASLD progression to fibrosis, cirrhosis and hepatocellular carcinoma (HCC).
Alfredo Caturano, Enes Erul, Roberto Nilo, Davide Nilo, Vincenzo Russo, Luca Rinaldi, Carlo Acierno, Erman Akkus, Katerina Koudelkova, Federica Cerini, Alessandro Rizzo, Ferdinando Carlo Sasso, Leonilde Bonfrate, Antonio Giordano, Hatime Arzu Yaşar, Caterina Conte   +15 more
wiley   +1 more source

Dapagliflozin and metabolic dysfunction-associated steatohepatitis.

BMJ
Haddad L, Marciano S.
europepmc   +1 more source

Is higher body mass index correlated with worse clinical outcomes in acute liver failure? [PDF]

World J Clin Cases
Kanda T, Sasaki-Tanaka R, Kamimura H, Terai S.   +3 more
europepmc   +1 more source

Translating Trial to Treatment: A Scoping Review of Resmetirom First Year in Real-World Use for Moderate to Advanced Fibrosis in Metabolic Dysfunction-Associated Steatohepatitis. [PDF]

Cureus
Vats K, Alam MM.
europepmc   +1 more source

SinglePass Kronos electrocautery device for closure after percutaneous medical liver biopsy: Five case reports. [PDF]

World J Gastroenterol
Misono AS, Oftadeh B, Nguyen V, Dang Q, Young L, Patel T, Techasith T, Mesipam A, Baker C, Velling T.   +9 more
europepmc   +1 more source

Correction: Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies. [PDF]

Front Med (Lausanne)
Habibullah M, Jemmieh K, Ouda A, Haider MZ, Malki MI, Elzouki AN.   +5 more
europepmc   +1 more source

Retrospective Study of Real-World Treatment Patterns of Subcutaneous Semaglutide Use Among Patients with Metabolic Dysfunction-Associated Steatohepatitis in the United States. [PDF]

Clinicoecon Outcomes Res
Kim Y, Zeng N, Winer-Jones JP, Bonafede M, Lobo F, O'Donnell J, Ryan T.   +6 more
europepmc   +1 more source

Decreased fatty liver index with tirzepatide treatment in Japanese patients with type 2 diabetes: A SURPASS J‐mono post hoc analysis

Diabetes, Obesity and Metabolism, EarlyView.
Masato Yoneda, Masakazu Takeuchi, Tomonori Oura, Atsushi Nakajima   +3 more
wiley   +1 more source